B of A Securities Upgrades Gilead Sciences to Buy, Raises Price Target to $95
Portfolio Pulse from Benzinga Newsdesk
B of A Securities analyst Geoff Meacham has upgraded Gilead Sciences from Neutral to Buy and raised the price target from $88 to $95.
September 08, 2023 | 11:30 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Gilead Sciences has been upgraded from Neutral to Buy by B of A Securities, with a raised price target from $88 to $95.
The upgrade from Neutral to Buy and the increase in price target by B of A Securities indicates a positive outlook for Gilead Sciences. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100